会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明专利
    • Pyrrolidine inhibitor of iap
    • 吡咯啉抑制剂IAP
    • JP2012184230A
    • 2012-09-27
    • JP2012064552
    • 2012-03-21
    • Genentech Incジェネンテック, インコーポレイテッド
    • COHEN FREDERICKTSUI VICKIE HSIAO-WEILY CUONGFLYGARE JOHN A
    • C07K5/06A61K38/00A61P35/00A61P43/00
    • C07D471/04C07D417/04C07D417/14
    • PROBLEM TO BE SOLVED: To provide novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies.SOLUTION: This invention relates to a compound of formula (I) (wherein A is a 5-membered aromatic heterocycle or the like incorporating 1 to 4 heteroatoms N, O, or S; Q is H, alkyl, a carbocycle, or a heterocycle; Xand Xare each independently O or S; Y is a bond, (CRR), O or S; n is 1 or 2; Ris H; or Rand Rtogether form a 5-8 membered heterocycle; Ris alkyl, a carbocycle or the like; Ris H or alkyl; or Rand Rtogether form a 3-6 heterocycle; R' is H; or Rand R' together form a 3-6 carbocycle; Rand R' are independently H, hydroxyl or the like; Ris H or alkyl; R, and R' are each independently H, alkyl or the like; Ris H, cyano or the like; and Ris H, alkyl or the like). The invention further relates to salts and solvates thereof.
    • 待解决的问题:提供可用作治疗恶性肿瘤的治疗剂的新的IAP抑制剂。 解决方案:本发明涉及式(I)化合物(其中A是含有1至4个杂原子N,O或S的5元芳香杂环等; Q是H,烷基,碳环, 或杂环; X 1 和X 2 各自独立地为O或S; Y为键(CR 7 R 7 n ,O或S; n为1或2; R 1 为H;或者R 1 和R 2 共同形成5 -8元杂环; R 8是苯基,碳环或类似基团; R 3是H或烷基;或R“ SB POS =“POST”> 3 和R 4 一起形成3-6杂环; R 3 是H;或R 3 和R 3 共同形成3-6个碳环; R 4 和R 4 独立地是H,羟基等; R“是H或烷基; R 6 ,R 6 各自独立地为H,烷基等; R 7是H,氰基等; 并且R 8是苯基,烷基等)。 本发明还涉及其盐和溶剂化物。 版权所有(C)2012,JPO&INPIT
    • 6. 发明申请
    • PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF
    • 。。。。。。。。。。。。
    • WO2014159981A3
    • 2015-04-09
    • PCT/US2014025564
    • 2014-03-13
    • SPIROGEN SARLGENENTECH INC
    • HOWARD PHILIP WILSONFLYGARE JOHN APILLOW THOMASWEI BINQING
    • A61K47/48A61K31/5517C07D487/04
    • A61K47/6869A61K31/5517A61K47/48638A61K47/6803A61K47/6851A61K47/6855A61K47/6889A61P35/00C07D487/04C07D519/00
    • Conjugate compounds of formula (A): wherein: R2 is, where R36a and R36b are independently selected from H, F, C1-4 saturated aikyl, C2-3 alkenyl, which alkyl and alkenyl groups are optionally substituted by a group selected from C1-4 alkyl amido and C1-4 alkyl ester; or, when one of R36a and R36b is H, the other is selected from nitrile and a C1-4 aikyl ester; R6 and R9 are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR', NO2, Me3Sn and halo; R7 is independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR', NO2, Me3Sn and halo; Y is selected from formulae A1, A2, A3, A4, A5 and A6: L is a linker connected to a cell binding agent; CBA is the cell binding agent; n is an integer selected in the range of 0 to 48; RA4 is a C1-6 alkylene group; either (a) R10 is H, and R11 is OH, ORA, where RA is C1-4 aikyl; or (b) R10 and R11 form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or (c) R10 is H and R11 is OSOzM, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation; R and R' are each independently selected from optionally substituted C1-12 alkyl, C3-20 heterocyclyl and C5-20 aryl groups, and optionally in relation to the group NRR', R and R' together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring; wherein R16, R17, R19, R20, R21 and R22 are as defined for R6, R7, R9, R10, R11 and R2 respectively; wherein Z is CH or N; wherein T and T' are independently selected from a single bond or a C1-9 alkylene, which chain may be interrupted by one or more heteroatoms e.g. O, S, N(H), NMe, provided that the number of atoms in the shortest chain of atoms between X and X' is 3 to 12 atoms; and X and X' are independently selected from O, S and N(H).
    • 式(A)的共轭化合物:其中:R 2为,其中R 36a和R 36b独立地选自H,F,C 1-4饱和的烷基,C 2-3链烯基,该烷基和烯基任选被选自C1 -4-烷基酰氨基和C 1-4烷基酯; 或者当R 36a和R 36b之一为H时,另一个选自腈和C 1-4烷基酯; R 6和R 9独立地选自H,R,OH,OR,SH,SR,NH 2,NHR,NRR',NO 2,Me 3 Sn和卤素; R 7独立地选自H,R,OH,OR,SH,SR,NH 2,NHR,NRR',NO 2,Me 3 Sn和卤素; Y选自式A1,A2,A3,A4,A5和A6:L是连接到细胞结合剂的连接体; CBA是细胞结合剂; n为0〜48的整数; RA4是C1-6亚烷基; (a)R 10是H,R 11是OH,ORA,其中RA是C 1-4烷基; 或(b)R 10和R 11在与它们结合的氮原子和碳原子之间形成氮 - 碳双键; 或(c)R 10为H且R 11为OSOzM,其中z为2或3,M为单价药学上可接受的阳离子; R和R'各自独立地选自任选取代的C 1-12烷基,C 3-20杂环基和C 5-20芳基,并且任选地相对于基团NRR',R和R'与它们所在的氮原子一起 连接形成任选取代的4-,5-,6-或7-元杂环; 其中R16,R17,R19,R20,R21和R22分别如R6,R7,R9,R10,R11和R2所定义; 其中Z是CH或N; 其中T和T'独立地选自单键或C1-9亚烷基,该链可以被一个或多个杂原子间隔。 O,S,N(H),NMe,条件是X和X'之间的最短原子链中的原子数为3至12个原子; X和X'独立地选自O,S和N(H)。